| 16407-9 |
Asbestos |
Prid |
Sputum |
Pt |
Nom |
Microscopy.light |
|
ACTIVE |
Asbestos identified in Sputum by Light microscopy |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16407-9 |
|
Microscopy.light |
|
|
Both |
|
|
|
0 |
Asbestos Spt Micro |
|
|
|
|
|
DRUG/TOXICOLOGY; Drugs; Identity or presence; LM; Lower respiratory; Micro; Micros; Microscopic; Nominal; Point in time; Random; Spt; Sputum |
2.78 |
1.0l |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Removed "Identified" from the component because it is implied by the Property "Prid"; |
0 |
| 16408-7 |
Ascorbate |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Ascorbate [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHEM |
|
16408-7 |
|
|
|
|
Both |
|
|
|
0 |
Vit C Ur-mCnc |
|
|
|
Y |
|
Ascorbic acid; c702; Chemistry; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn; Vit C; Vitamin C |
2.73 |
1.0l |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 16409-5 |
Ascorbate^post dose |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Ascorbate [Mass/volume] in Serum or Plasma --post dose |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
16409-5 |
|
|
|
|
Observation |
|
|
|
0 |
Vit C p dose SerPl-mCnc |
|
|
|
Y |
|
After; Ascorbic acid; c702; CHEMISTRY.CHALLENGE TESTING; Level; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Vit C; Vitamin C |
2.34 |
1.0l |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 1641-0 |
Thyrotropin^1H post dose TRH IV |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
DISCOURAGED |
Thyrotropin [Mass/volume] in Serum or Plasma --1 hour post dose TRH IV |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
CHAL |
|
1641-0 |
|
|
|
|
Observation |
|
|
|
0 |
TSH 1h p TRH IV SerPl-mCnc |
|
|
|
Y |
|
1 hour; 1.0Hr; 1h p TRH; 1h p TRH IV; 60 min; 60 minutes; 60M; 60min; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Level; Mass concentration; p dose; p TRH; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Thyroid stimulating hormone; Thyrotropic hormone; TSH |
2.73 |
1 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 16410-3 |
Asparagine |
PrThr |
Urine |
Pt |
Ord |
|
|
ACTIVE |
Asparagine [Presence] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
16410-3 |
|
|
|
|
Observation |
|
|
|
0 |
Asparagine Ur Ql |
|
|
|
|
|
Asn; Chemistry; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 16411-1 |
Aspartate |
PrThr |
Urine |
Pt |
Ord |
|
|
ACTIVE |
Aspartate [Presence] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
16411-1 |
|
|
|
|
Observation |
|
|
|
0 |
Aspartate Ur Ql |
|
|
|
|
|
Asp; Aspartic acid; Chemistry; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.56 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 16412-9 |
Aspartate aminotransferase |
CCnc |
RBC |
Pt |
Qn |
|
|
ACTIVE |
Aspartate aminotransferase [Enzymatic activity/volume] in Red Blood Cells |
|
MIN |
DefinitionDescription |
|
|
arb U/L |
|
|
|
|
|
|
CHEM |
|
16412-9 |
|
|
|
|
Both |
|
|
|
0 |
AST RBC-cCnc |
|
|
|
Y |
|
Asp; Aspartate amino transferase; Aspartate transaminase; Aspartic acid; AST; Catalytic Concentration; Chemistry; Erythrocytes; Glutamic oxaloacetic transaminase; Hepatology; Liver; Point in time; QNT; Quan; Quant; Quantitative; Random; Red blood cells; Red blood corpusles; SGOT |
2.68 |
1.0l |
|
|
|
|
|
|
|
U/L |
|
|
|
0 |
| 16414-5 |
Aspergillus amstelodami Ab |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Aspergillus amstelodami Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ALLERGY |
|
16414-5 |
|
|
|
|
Both |
|
|
|
0 |
A amstelodami Ab Qn |
|
|
|
Y |
|
A amstelodami; ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Asperg; Aspergil; Aspergilis; Aspergilla; Aspergillin; Aspergillosis; Aspergils; Aspergilus; Autoantibodies; Autoantibody; m40; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.69 |
1.0l |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 16415-2 |
Aspergillus flavus Ab |
PrThr |
CSF |
Pt |
Ord |
|
|
ACTIVE |
Aspergillus flavus Ab [Presence] in Cerebral spinal fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16415-2 |
|
|
|
|
Both |
|
|
|
0 |
A flavus Ab CSF Ql |
|
|
|
|
|
A flavus; ABS; Aby; Antby; Anti; Antibodies; Antibody; Asperg; Aspergil; Aspergilis; Aspergilla; Aspergillin; Aspergillosis; Aspergils; Aspergilus; Autoantibodies; Autoantibody; Cerebral spinal fluid; Cerebrospinal Fl; Farmers lung; ID; Infectious Disease; InfectiousDisease; m228; m311; m54; Microbiology; Neuro; Neurology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 16416-0 |
Aspergillus terreus Ab |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Aspergillus terreus Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ALLERGY |
|
16416-0 |
|
|
|
|
Both |
|
|
|
0 |
A terreus Ab Qn |
|
|
|
Y |
|
A terreus; ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Asperg; Aspergil; Aspergilis; Aspergilla; Aspergillin; Aspergillosis; Aspergils; Aspergilus; Autoantibodies; Autoantibody; Farmers lung; m309; m36; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.69 |
1.0l |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 16417-8 |
Aspergillus versicolor Ab |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Aspergillus versicolor Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ALLERGY |
|
16417-8 |
|
|
|
|
Both |
|
|
|
0 |
A versicolor Ab Qn |
|
|
|
Y |
|
A versicolor; ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Asperg; Aspergil; Aspergilis; Aspergilla; Aspergillin; Aspergillosis; Aspergils; Aspergilus; Autoantibodies; Autoantibody; Farmers lung; m019; m19; m25; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.69 |
1.0l |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 16418-6 |
Azatadine |
PrThr |
Urine |
Pt |
Ord |
|
|
ACTIVE |
Azatadine [Presence] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16418-6 |
|
|
|
|
Both |
|
|
|
0 |
Azatadine Ur Ql |
|
|
|
|
|
C20H22N2; DRUG/TOXICOLOGY; Drugs; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.56 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 16419-4 |
azaTHIOprine |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
azaTHIOprine [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
16419-4 |
|
|
|
|
Both |
|
|
|
0 |
azaTHIOprine SerPl-mCnc |
|
|
|
Y |
|
AZA; Azatioprin; C9H7N7O2S; CCUCOL; Cytostatics; DRUG/TOXICOLOGY; Drugs; Imuran; Imurek; Imurel; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 1642-8 |
Thyrotropin^baseline |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
DISCOURAGED |
Thyrotropin [Mass/volume] in Serum or Plasma --baseline |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
CHAL |
|
1642-8 |
|
|
|
|
Observation |
|
|
|
0 |
TSH BS SerPl-mCnc |
|
|
|
Y |
|
BS; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Thyroid stimulating hormone; Thyrotropic hormone; TSH |
2.73 |
1 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 16420-2 |
Azithromycin |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Azithromycin [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
16420-2 |
|
|
|
|
Both |
|
|
|
0 |
Azithromycin SerPl-mCnc |
|
|
|
Y |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Zithromax |
2.73 |
1.0l |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 16421-0 |
Azithromycin+Ethambutol |
Susc |
Isolate |
Pt |
OrdQn |
MIC |
|
ACTIVE |
Azithromycin+Ethambutol [Susceptibility] by Minimum inhibitory concentration (MIC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
16421-0 |
|
MIC |
|
|
Observation |
|
|
|
0 |
Azithro+Ethambut Islt MIC |
|
|
|
|
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Azithro+Ethambut; Etambol; Ethamb; ID; Inagen; Infectious Disease; InfectiousDisease; Islt; Isol; Minimum inhibitory concentration; Myambutol; Mycobutol; Olbutam; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Zithromax |
2.19 |
1.0l |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 16422-8 |
Azlocillin |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Azlocillin [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16422-8 |
|
|
|
|
Both |
|
|
|
0 |
Azlocillin Ur-mCnc |
|
|
|
Y |
|
Azlin; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Securopen; UA; UR; Urn |
2.34 |
1.0l |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 16423-6 |
Aztreonam |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Aztreonam [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
16423-6 |
|
|
|
|
Both |
|
|
|
0 |
Aztreonam Ur-mCnc |
|
|
|
Y |
|
Azactam; Azaj; azthreonam; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.42 |
1.0l |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 16424-4 |
Salicylazosulfapyridine |
MCnc |
Ser |
Pt |
Qn |
|
|
DEPRECATED |
Deprecated sulfaSALAzine [Mass/volume] in Serum or Plasma |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16424-4 |
|
|
|
|
|
|
|
|
0 |
Deprecated Salicylazosulfapyridine Ser |
|
|
|
|
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.36 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 16425-1 |
Babesia sp Ab.IgM |
ACnc |
Ser |
Pt |
Qn |
IF |
|
ACTIVE |
Babesia sp IgM Ab [Units/volume] in Serum by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16425-1 |
|
IF |
|
|
Both |
|
|
|
0 |
Babesia IgM Ser IF-aCnc |
|
|
|
Y |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Arbitrary concentration; Autoantibodies; Autoantibody; Babesiosis; FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin M; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin M; Infectious Disease; InfectiousDisease; Microbiology; Piroplasmosis; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; species; spp; SR; Time Resolved Fluorescence; TRF |
2.69 |
1.0l |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 16426-9 |
Babesia sp Ab.IgM |
Titr |
Ser |
Pt |
SemiQn |
|
|
ACTIVE |
Babesia sp IgM Ab [Titer] in Serum |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
16426-9 |
|
|
|
|
Both |
|
|
|
0 |
Babesia IgM Titr Ser |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Babesiosis; Dilution factor; Dilution Factor (Titer); ID; Immune globulin M; Immunoglobulin M; Infectious Disease; InfectiousDisease; Microbiology; Piroplasmosis; Point in time; Random; Serum; SmQn; species; spp; SR; Titer; Titered; Titre; Ttr |
2.75 |
1.0l |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 16427-7 |
Babesia microti Ab |
Titr |
Ser |
Pt |
SemiQn |
|
|
ACTIVE |
Babesia microti Ab [Titer] in Serum |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
16427-7 |
|
|
|
|
Both |
|
|
|
0 |
B microti Ab Titr Ser |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; B microti; Babesiosis; Dilution factor; Dilution Factor (Titer); ID; Infectious Disease; InfectiousDisease; Microbiology; Piroplasmosis; Point in time; Random; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
1.0l |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 16428-5 |
Bacitracin |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Bacitracin [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
16428-5 |
|
|
|
|
Both |
|
|
|
0 |
Bacitracin SerPl-mCnc |
|
|
|
Y |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.42 |
1.0l |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 16429-3 |
Barbiturates |
PrThr |
Urine |
Pt |
Ord |
Confirm |
|
ACTIVE |
Barbiturates [Presence] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16429-3 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Barbiturates Ur Ql Cfm |
|
|
|
|
|
Addiction; Barb; Barbiturate; Barbs; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; GCMS; Illicit; LC/MS/MS; Ordinal; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 1643-6 |
Thyrotropin^pre dose TRH IV |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
DISCOURAGED |
Thyrotropin [Mass/volume] in Serum or Plasma --pre dose TRH IV |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
CHAL |
|
1643-6 |
|
|
|
|
Observation |
|
|
|
0 |
TSH pre TRH IV SerPl-mCnc |
|
|
|
Y |
|
Before; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; pre TRH; pre TRH IV; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Thyroid stimulating hormone; Thyrotropic hormone; TSH |
2.42 |
1 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
